Real-World Outcomes of Elacestrant in ER+, HER2−, <i>ESR1</i> -Mutant Metastatic Breast Cancer
Elacestrant demonstrated a durable benefit in real-world clinical practice, particularly in earlier lines and in patients with prolonged prior ET exposure. Despite coexisting ESR1 and PI3K pathway mutations, TTNT remained clinically meaningful, reinforcing the role of elacestrant in personalized ET sequencing strategies prior to chemotherapy, antibody-drug conjugates, or targeted combinations. See related article by Lloyd et al., p. 169.
Authors
- Reshma Mahtani (ORCID: https://orcid.org/0000-0002-7711-8627)
- Jessica Maitland (ORCID: https://orcid.org/0009-0002-6804-319X)
- Heather L. McArthur (ORCID: https://orcid.org/0000-0002-0201-3871)
- Seth A. Wander (ORCID: https://orcid.org/0000-0002-4127-4708)
- Mark D. Pegram (ORCID: https://orcid.org/0000-0002-9743-8118)
- Virginia Kaklamani (ORCID: https://orcid.org/0000-0002-3313-8458)
- Sebastian Kloss (ORCID: https://orcid.org/0000-0003-0730-2645)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- William J. Gradishar (ORCID: https://orcid.org/0000-0002-2772-3140)
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
- Elyse Swallow (ORCID: https://orcid.org/0000-0002-1634-142X)
- Hope S. Rugo (ORCID: https://orcid.org/0000-0001-6710-4814)
- Tomer Wasserman (ORCID: https://orcid.org/0009-0007-2468-8371)
Institutions
- Northwestern University (US)
- Cedars-Sinai Medical Center (US)
- Baptist Hospital of Miami (US)
- City Of Hope National Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Yale Cancer Center (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Southwestern Medical Center (US)
- Menarini Group (Italy) (IT)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
- Innovative Research Group (Canada) (CA)
- Palo Alto Institute (US)
- Analysis Group (United States) (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3040
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Menarini Group